-
1
-
-
77955635233
-
Cancer statistics, 2010
-
20610543
-
A Jemal, et al. 2010 Cancer statistics, 2010 CA Cancer J Clin. 60 5 277 300 20610543
-
(2010)
CA Cancer J Clin.
, vol.60
, Issue.5
, pp. 277-300
-
-
Jemal, A.1
-
2
-
-
40549134987
-
Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults
-
DOI 10.1002/jso.20972
-
AF Nascimento CP Raut 2008 Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults J Surg Oncol. 97 4 330 339 18286476 (Pubitemid 351358581)
-
(2008)
Journal of Surgical Oncology
, vol.97
, Issue.4
, pp. 330-339
-
-
Nascimento, A.F.1
Raut, C.P.2
-
3
-
-
0043132269
-
Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time
-
DOI 10.1200/JCO.2003.02.026
-
J Weitz CR Antonescu MF Brennan 2003 Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time J Clin Oncol. 21 14 2719 2725 12860950 (Pubitemid 46606317)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.14
, pp. 2719-2725
-
-
Weitz, J.1
Antonescu, C.R.2
Brennan, M.F.3
-
4
-
-
34249723214
-
Opportunities for improving the therapeutic ratio for patients with sarcoma
-
DOI 10.1016/S1470-2045(07)70169-9, PII S1470204507701699
-
JS Wunder, et al. 2007 Opportunities for improving the therapeutic ratio for patients with sarcoma Lancet Oncol. 8 6 513 524 17540303 (Pubitemid 46823060)
-
(2007)
Lancet Oncology
, vol.8
, Issue.6
, pp. 513-524
-
-
Wunder, J.S.1
Nielsen, T.O.2
Maki, R.G.3
O'Sullivan, B.4
Alman, B.A.5
-
5
-
-
41149169284
-
Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients
-
DOI 10.1002/cncr.23332
-
V Karavasilis, et al. 2008 Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer. 112 7 1585 1591 18278813 (Pubitemid 351441172)
-
(2008)
Cancer
, vol.112
, Issue.7
, pp. 1585-1591
-
-
Karavasilis, V.1
Seddon, B.M.2
Ashley, S.3
Al-Muderis, O.4
Fisher, C.5
Judson, I.6
-
6
-
-
0032952928
-
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline- containing first-line regimens - A European organization for research and treatment of cancer soft tissue and bone sarcoma group study
-
M Van Glabbeke, et al. 1999 Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol. 17 1 150 157 10458228 A large meta-analysis to determine the efficacy of anthracycline regimens in treatment of sarcoma in the first-line setting (Pubitemid 29022388)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.1
, pp. 150-157
-
-
Van Glabbeke, M.1
Van Oosterom, A.T.2
Oosterhuis, J.W.3
Mouridsen, H.4
Crowther, D.5
Somers, R.6
Verweij, J.7
Santoro, A.8
Buesa, J.9
Tursz, T.10
-
7
-
-
59449090129
-
MFH revisited: Outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities-an analysis of 140 patients
-
18584203
-
M Lehnhardt, et al. 2009 MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities-an analysis of 140 patients Langenbecks Arch Surg. 394 2 313 320 18584203
-
(2009)
Langenbecks Arch Surg.
, vol.394
, Issue.2
, pp. 313-320
-
-
Lehnhardt, M.1
-
8
-
-
34848882533
-
Soft tissue sarcomas: The role of histology and molecular pathology for differential diagnosis
-
17867581 1:CAS:528:DC%2BD2sXitVaru7c%3D
-
C Poremba 2006 Soft tissue sarcomas: the role of histology and molecular pathology for differential diagnosis Verh Dtsch Ges Pathol. 90 59 72 17867581 1:CAS:528:DC%2BD2sXitVaru7c%3D
-
(2006)
Verh Dtsch Ges Pathol.
, vol.90
, pp. 59-72
-
-
Poremba, C.1
-
9
-
-
68249145205
-
Pathology of soft-tissue tumors: Daily diagnosis, molecular cytogenetics and experimental approach
-
19627534 1:CAS:528:DC%2BD1MXhtFWjtLzF
-
H Iwasaki, et al. 2009 Pathology of soft-tissue tumors: daily diagnosis, molecular cytogenetics and experimental approach Pathol Int. 59 8 501 521 19627534 1:CAS:528:DC%2BD1MXhtFWjtLzF
-
(2009)
Pathol Int.
, vol.59
, Issue.8
, pp. 501-521
-
-
Iwasaki, H.1
-
10
-
-
0023176119
-
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas
-
EC Borden, et al. 1987 Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas J Clin Oncol. 5 6 840 850 3585441 1:STN:280:DyaL2s3isFWjtA%3D%3D (Pubitemid 17119988)
-
(1987)
Journal of Clinical Oncology
, vol.5
, Issue.6
, pp. 840-850
-
-
Borden, E.C.1
Amato, D.A.2
Rosenbaum, C.3
-
11
-
-
80051666640
-
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
-
EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study
-
Gelderblom H, et al. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. ASCO Meeting Abstracts. 2010;28(15 suppl):10037.
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 10037
-
-
Gelderblom, H.1
-
12
-
-
18844475615
-
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
-
DOI 10.1016/S0959-8049(01)00050-8, PII S0959804901000508
-
I Judson, et al. 2001 Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer. 37 7 870 877 11313175 1:CAS:528:DC%2BD3MXislGhtb0%3D (Pubitemid 32323965)
-
(2001)
European Journal of Cancer
, vol.37
, Issue.7
, pp. 870-877
-
-
Judson, I.1
Radford, J.A.2
Harris, M.3
Blay, J.-Y.4
Van Hoesel, Q.5
Le Cesne, A.6
Van Oosterom, A.T.7
Clemons, M.J.8
Kamby, C.9
Hermans, C.10
Whittaker, J.11
Donato Di Paola, E.12
Verweij, J.13
Nielsen, S.14
-
13
-
-
34547688913
-
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study
-
DOI 10.1200/JCO.2006.09.7717
-
P Lorigan, et al. 2007 Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol. 25 21 3144 3150 17634494 1:CAS:528:DC%2BD2sXptlGrt7k%3D (Pubitemid 47218064)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.21
, pp. 3144-3150
-
-
Lorigan, P.1
Verweij, J.2
Papai, Z.3
Rodenhuis, S.4
Le Cesne, A.5
Leahy, M.G.6
Radford, J.A.7
Van Glabbeke, M.M.8
Kirkpatrick, A.9
Hogendoorn, P.C.W.10
Blay, J.-Y.11
-
14
-
-
64749115863
-
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas
-
19273704 1:CAS:528:DC%2BD1MXltlSisbY%3D
-
J Maurel, et al. 2009 Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas J Clin Oncol. 27 11 1893 1898 19273704 1:CAS:528:DC%2BD1MXltlSisbY%3D
-
(2009)
J Clin Oncol.
, vol.27
, Issue.11
, pp. 1893-1898
-
-
Maurel, J.1
-
15
-
-
0023428586
-
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group
-
3479329 1:STN:280:DyaL1c%2FlsFajtw%3D%3D
-
HT Mouridsen, et al. 1987 Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer Clin Oncol. 23 10 1477 1483 3479329 1:STN:280:DyaL1c%2FlsFajtw%3D%3D
-
(1987)
Eur J Cancer Clin Oncol.
, vol.23
, Issue.10
, pp. 1477-1483
-
-
Mouridsen, H.T.1
-
16
-
-
7844252263
-
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
-
OS Nielsen, et al. 1998 High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group Br J Cancer. 78 12 1634 1639 9862576 1:CAS:528:DyaK1MXhslKltg%3D%3D (Pubitemid 28550051)
-
(1998)
British Journal of Cancer
, vol.78
, Issue.12
, pp. 1634-1639
-
-
Nielsen, O.S.1
Dombernowsky, P.2
Mouridsen, H.3
Crowther, D.4
Verweij, J.5
Buesa, J.6
Steward, W.7
Daugaard, S.8
Van Glabbeke, M.9
Kirkpatrick, A.10
Tursz, T.11
-
17
-
-
0029005580
-
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
-
7602342 1:STN:280:DyaK2MzisFylug%3D%3D
-
A Santoro, et al. 1995 Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol. 13 7 1537 1545 7602342 1:STN:280:DyaK2MzisFylug%3D%3D A large randomized phase 3 study demonstrating no statistically significant difference in ORR or OS between doxorubicin alone compared to doxorubicin plus ifosfamide
-
(1995)
J Clin Oncol.
, vol.13
, Issue.7
, pp. 1537-1545
-
-
Santoro, A.1
-
18
-
-
18144448739
-
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
-
J Verweij, et al. 2000 Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group J Clin Oncol. 18 10 2081 2086 10811673 1:CAS:528:DC%2BD3cXktVyjsLY%3D (Pubitemid 30324361)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.10
, pp. 2081-2086
-
-
Verweij, J.1
Lee, S.M.2
Ruka, W.3
Buesa, J.4
Coleman, R.5
Van Hoessel, R.6
Seynaeve, C.7
Di Paola, E.D.8
Van Glabbeke, M.9
Tonelli, D.10
Judson, I.R.11
-
19
-
-
0027256397
-
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas
-
JH Edmonson, et al. 1993 Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J Clin Oncol. 11 7 1269 1275 8315424 1:STN:280:DyaK3szgtFKlsg%3D%3D A randomized phase 3 study demonstrating that ifosfamide plus doxorubicin yields a statistically significant increase in ORR compared to doxorubicin alone, but both regimens lead to similar overall survival outcomes (Pubitemid 23199129)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.7
, pp. 1269-1275
-
-
Edmonson, J.H.1
Ryan, L.M.2
Blum, R.H.3
Brooks, J.S.J.4
Shiraki, M.5
Frytak, S.6
Parkinson, D.R.7
-
20
-
-
71049122368
-
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
-
19853437 1:CAS:528:DC%2BD1MXhsFGrsbvF
-
S Sleijfer, et al. 2010 Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur J Cancer. 46 1 72 83 19853437 1:CAS:528:DC%2BD1MXhsFGrsbvF An important meta-analysis that establishes the prognostic and predictive factors for outcome of ifosfamide-containing regimens compared to doxorubicin-containing therapy in the first-line setting. Also important for benchmarks of single-agent doxorubicin
-
(2010)
Eur J Cancer.
, vol.46
, Issue.1
, pp. 72-83
-
-
Sleijfer, S.1
-
21
-
-
80051663984
-
-
Adriamycin, [package insert]. USA: Pharmacia & Upjohn, 1997
-
Adriamycin, [package insert]. USA: Pharmacia & Upjohn, 1997.
-
-
-
-
22
-
-
77953931502
-
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
-
20587042
-
LA Smith, et al. 2010 Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer. 10 337 20587042 A systematic review and meta-analysis to identify the risk of cardiotoxicity of anthracycline agents
-
(2010)
BMC Cancer.
, vol.10
, pp. 337
-
-
Smith, L.A.1
-
23
-
-
0026042237
-
A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors
-
1873773 1:STN:280:DyaK3MzjvFSqtA%3D%3D
-
ES Casper, et al. 1991 A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors Cancer. 68 6 1221 1229 1873773 1:STN:280:DyaK3MzjvFSqtA%3D%3D
-
(1991)
Cancer.
, vol.68
, Issue.6
, pp. 1221-1229
-
-
Casper, E.S.1
-
24
-
-
0025770430
-
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study
-
2067035 1:STN:280:DyaK3M3psFagsA%3D%3D
-
M Zalupski, et al. 1991 Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study J Natl Cancer Inst. 83 13 926 932 2067035 1:STN:280:DyaK3M3psFagsA%3D%3D
-
(1991)
J Natl Cancer Inst.
, vol.83
, Issue.13
, pp. 926-932
-
-
Zalupski, M.1
-
25
-
-
0033929703
-
Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC soft tissue and bone sarcoma group
-
OS Nielsen, et al. 2000 Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue Sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma Group Sarcoma. 4 1-2 31 35 18521432 1:CAS:528: DC%2BD3cXlslCqu7s%3D (Pubitemid 30480279)
-
(2000)
Sarcoma
, vol.4
, Issue.1-2
, pp. 31-35
-
-
Nielsen, O.S.1
Dombernowsky, P.2
Mouridsen, H.3
Daugaard, S.4
Van Glabbeke, M.5
Kirkpatrick, A.6
Verweij, J.7
-
26
-
-
0021997261
-
Phase II trial of mitoxantrone in advanced sarcomas: A Southwest Oncology Group study
-
FE Bull, et al. 1985 Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study Cancer Treat Rep. 69 2 231 233 3882233 1:STN:280:DyaL2M7isVCrtQ%3D%3D (Pubitemid 15170466)
-
(1985)
Cancer Treatment Reports
, vol.69
, Issue.2
, pp. 231-233
-
-
Bull, F.E.1
Von Hoff, D.D.2
Balcerzak, S.P.3
-
27
-
-
0023442506
-
Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas
-
3119206 1:STN:280:DyaL1c%2Flt1Oitw%3D%3D
-
I Quirt, et al. 1987 Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas Cancer Treat Rep. 71 11 1109 1110 3119206 1:STN:280:DyaL1c%2Flt1Oitw%3D%3D
-
(1987)
Cancer Treat Rep.
, vol.71
, Issue.11
, pp. 1109-1110
-
-
Quirt, I.1
-
28
-
-
77957241407
-
Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion
-
20795769 1:CAS:528:DC%2BC3cXht1SnsbbF
-
WW Huh, et al. 2010 Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion Pediatr Hematol Oncol. 27 7 546 557 20795769 1:CAS:528:DC%2BC3cXht1SnsbbF
-
(2010)
Pediatr Hematol Oncol.
, vol.27
, Issue.7
, pp. 546-557
-
-
Huh, W.W.1
-
29
-
-
0031983153
-
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas
-
M Lopez, et al. 1998 Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas J Clin Oncol. 16 1 86 92 9440727 1:CAS:528:DyaK1cXmtleqtQ%3D%3D (Pubitemid 28041583)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.1
, pp. 86-92
-
-
Lopez, M.1
Vici, P.2
Di Lauro, L.3
Conti, F.4
Paoletti, G.5
Ferraironi, A.6
Sciuto, R.7
Giannarelli, D.8
Maini, C.L.9
-
30
-
-
0033879520
-
Phase II trial of liposomal doxorubicin (Doxil®) in advanced soft tissue sarcomas
-
DOI 10.1023/A:1006429907449
-
T Chidiac, et al. 2000 Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas Invest New Drugs. 18 3 253 259 10958594 1:CAS:528:DC%2BD3cXmsVGhtLY%3D (Pubitemid 30599146)
-
(2000)
Investigational New Drugs
, vol.18
, Issue.3
, pp. 253-259
-
-
Chidiac, T.1
Budd, G.T.2
Pelley, R.3
Sandstrom, K.4
McLain, D.5
Elson, P.6
Crownover, R.7
Marks, K.8
Muschler, G.9
Joyce, M.10
Zehr, R.11
Bukowski, R.12
-
31
-
-
0037740979
-
Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in sarcoma
-
DOI 10.1081/CNV-120016412
-
KM Skubitz 2003 Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma Cancer Investig. 21 2 167 176 1:CAS:528:DC%2BD3sXktVOmu70%3D (Pubitemid 36532162)
-
(2003)
Cancer Investigation
, vol.21
, Issue.2
, pp. 167-176
-
-
Skubitz, K.M.1
-
32
-
-
0034109686
-
Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: A phase II study of the Italian Sarcoma Group (ISG)
-
S Toma, et al. 2000 Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG) Anticancer Res. 20 1B 485 491 10769710 1:CAS:528:DC%2BD3cXisl2gurc%3D (Pubitemid 30189706)
-
(2000)
Anticancer Research
, vol.20
, Issue.1 B
, pp. 485-491
-
-
Toma, S.1
Tucci, A.2
Villani, G.3
Carteni, G.4
Spadini, N.5
Palumbo, R.6
-
34
-
-
33746601850
-
A Phase II nonrandomised open-label study of liposomal Daunorubicin (DaunoXome) in advanced soft tissue Sarcoma
-
17040090
-
A McTiernan, et al. 2006 A Phase II nonrandomised open-label study of liposomal Daunorubicin (DaunoXome) in advanced soft tissue Sarcoma Sarcoma. 2006 1 41080 17040090
-
(2006)
Sarcoma.
, vol.2006
, Issue.1
, pp. 41080
-
-
McTiernan, A.1
-
35
-
-
27244450145
-
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
-
16192597
-
DR D'Adamo, et al. 2005 Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas J Clin Oncol. 23 28 7135 7142 16192597
-
(2005)
J Clin Oncol.
, vol.23
, Issue.28
, pp. 7135-7142
-
-
D'Adamo, D.R.1
-
36
-
-
36849015252
-
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas
-
DOI 10.1634/theoncologist.12-11-1351
-
M Tascilar, et al. 2007 The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas Oncologist. 12 11 1351 1360 18055856 1:CAS:528:DC%2BD1cXivVShtQ%3D%3D (Pubitemid 350232609)
-
(2007)
Oncologist
, vol.12
, Issue.11
, pp. 1351-1360
-
-
Tascilar, M.1
Loos, W.J.2
Seynaeve, C.3
Verweij, J.4
Sleijfer, S.5
-
37
-
-
0027533415
-
Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group
-
8453694
-
VH Bramwell, et al. 1993 Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group Cancer Chemother Pharmacol. 31 Suppl 2 S180 S184 8453694
-
(1993)
Cancer Chemother Pharmacol.
, vol.31
, Issue.SUPPL. 2
-
-
Bramwell, V.H.1
-
38
-
-
0032445542
-
Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas
-
M Lopez, et al. 1998 Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas Clin Ter. 149 5 331 333 10052244 1:STN:280:DyaK1M7mtFeqtA%3D%3D (Pubitemid 29069581)
-
(1998)
Clinica Terapeutica
, vol.149
, Issue.5
, pp. 331-333
-
-
Lopez, M.1
Carpano, S.2
Amodio, A.3
Gionfra, T.4
Giulia, M.D.5
Foggi, P.6
Manfredi, C.7
Del Monte, G.8
-
39
-
-
0036892122
-
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients
-
DOI 10.1016/S0959-8049(02)00491-4, PII S0959804902004914
-
AT van Oosterom, et al. 2002 Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients Eur J Cancer. 38 18 2397 2406 12460784 (Pubitemid 35387492)
-
(2002)
European Journal of Cancer
, vol.38
, Issue.18
, pp. 2397-2406
-
-
Van Oosterom, A.T.1
Mouridsen, H.T.2
Nielsen, O.S.3
Dombernowsky, P.4
Krzemieniecki, K.5
Judson, I.6
Svancarova, L.7
Spooner, D.8
Hermans, C.9
Van Glabbeke, M.10
Verweij, J.11
-
40
-
-
7344222584
-
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)
-
DOI 10.1023/A:1008474802882
-
JM Buesa, et al. 1998 Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol. 9 8 871 876 9789610 1:STN:280: DyaK1M%2Fgs1Sguw%3D%3D (Pubitemid 28440446)
-
(1998)
Annals of Oncology
, vol.9
, Issue.8
, pp. 871-876
-
-
Buesa, J.M.1
Lopez-Pousa, A.2
Martin, J.3
Anton, A.4
Garcia Del Muro, J.5
Bellmunt, J.6
Arranz, F.7
Valenti, V.8
Escudero, P.9
Menendez, D.10
Casado, A.11
Poveda, A.12
-
41
-
-
0030726408
-
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas
-
DOI 10.1023/A:1008279426654
-
R Palumbo, et al. 1997 Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas Ann Oncol. 8 11 1159 1162 9426338 1:STN:280:DyaK1c%2FoslOiug%3D%3D (Pubitemid 27521226)
-
(1997)
Annals of Oncology
, vol.8
, Issue.11
, pp. 1159-1162
-
-
Palumbo, R.1
Palmeri, S.2
Antimi, M.3
Gatti, C.4
Raffo, P.5
Villani, G.6
Toma, S.7
-
42
-
-
0030912403
-
High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - Dose-response and schedule dependence
-
SR Patel, et al. 1997 High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence J Clin Oncol. 15 6 2378 2384 9196153 1:CAS:528:DyaK2sXkt1ersb4%3D (Pubitemid 27251141)
-
(1997)
Journal of Clinical Oncology
, vol.15
, Issue.6
, pp. 2378-2384
-
-
Patel, S.R.1
Vadhan-Raj, S.2
Papadopolous, N.3
Plager, C.4
Burgess, M.A.5
Hays, C.6
Benjamin, R.S.7
-
43
-
-
0032870341
-
Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients
-
DOI 10.1023/A:1008386000547
-
T Cerny, et al. 1999 Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK) Ann Oncol. 10 9 1087 1094 10572607 1:STN:280:DC%2BD3c%2FjvV2jsA%3D%3D (Pubitemid 29482464)
-
(1999)
Annals of Oncology
, vol.10
, Issue.9
, pp. 1087-1094
-
-
Cerny, T.1
Leyvraz, S.2
Von Briel, T.3
Kupfer, A.4
Schaad, R.5
Hsu Schmitz, S.-F.6
Honegger, P.7
Sessa, C.8
Brunner, J.9
Boddy, A.V.10
-
44
-
-
0031706550
-
High-dose ifosfamide for soft tissue sarcomas: Set the scene, or senescence?: Editorial
-
DOI 10.1023/A:1008461922040
-
J Verweij 1998 High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence? Ann Oncol. 9 8 807 809 9789601 1:STN:280: DyaK1M%2Fgs1Sgsg%3D%3D (Pubitemid 28440437)
-
(1998)
Annals of Oncology
, vol.9
, Issue.8
, pp. 807-809
-
-
Verweij, J.1
-
45
-
-
0028284326
-
Synovial sarcoma: Uniform response of metastases to high dose ifosfamide
-
DOI 10.10 02/1097-0142(199 40515)73:10<2506::AID-CN CR2820731009>3.0.CO;2-S
-
G Rosen, et al. 1994 Synovial sarcoma. Uniform response of metastases to high dose ifosfamide Cancer. 73 10 2506 2511 8174046 1:STN:280: DyaK2c3ivVCgsQ%3D%3D (Pubitemid 24155525)
-
(1994)
Cancer
, vol.73
, Issue.10
, pp. 2506-2511
-
-
Rosen, G.1
Forscher, C.2
Lowenbraun, S.3
Eilber, F.4
Eckardt, J.5
Holmes, C.6
Fu, Y.S.7
-
46
-
-
71949085741
-
Preliminary efficacy and safety results of glufosfamide (GLU) in relapsed soft tissue sarcoma: Results of a phase II trial
-
D'Amato GZ, et al. Preliminary efficacy and safety results of glufosfamide (GLU) in relapsed soft tissue sarcoma: results of a phase II trial. ASCO Meeting Abstracts. 2008;26(15 suppl):10591.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, Issue.15 SUPPL.
, pp. 10591
-
-
D'Amato, G.Z.1
-
47
-
-
77957936131
-
A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO)
-
Verschraegen CF, et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). ASCO Meeting Abstracts. 2010;28(15 suppl):10004.
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 10004
-
-
Verschraegen, C.F.1
-
48
-
-
0027522607
-
Epirubicin and ifosfamide in advanced soft tissue sarcoma: A phase II study
-
B Chevallier, et al. 1993 Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study Cancer Investig. 11 2 135 139 1:STN:280:DyaK3s3hsVymtA%3D%3D (Pubitemid 23105029)
-
(1993)
Cancer Investigation
, vol.11
, Issue.2
, pp. 135-139
-
-
Chevallier, B.1
Leyvraz, S.2
Olivier, J.P.3
Fargeot, P.4
Facchini, T.5
Vo Van, M.L.6
-
49
-
-
0033941746
-
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus infosfamide plus recombinant human granulocyte-macrophage colony- stimulating factor in advanced soft tissue sarcomas: A trial of the european organization for research and treatment of cancer/soft tissue and bone sarcoma group
-
A Le Cesne, et al. 2000 Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group J Clin Oncol. 18 14 2676 2684 10894866 (Pubitemid 30463549)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.14
, pp. 2676-2684
-
-
Le Cesne, A.1
Judson, I.2
Crowther, D.3
Rodenhuis, S.4
Keizer, H.J.5
Van Hoesel, Q.6
Blay, J.Y.7
Frisch, J.8
Van Glabbeke, M.9
Hermans, C.10
Van Oosterom, A.11
Tursz, T.12
Verweij, J.13
-
50
-
-
33751037747
-
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
-
DOI 10.1038/sj.bjc.6603420, PII 6603420
-
S Leyvraz, et al. 2006 Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies Br J Cancer. 95 10 1342 1347 17031396 1:CAS:528:DC%2BD28XhtF2ns77J (Pubitemid 44760083)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.10
, pp. 1342-1347
-
-
Leyvraz, S.1
Herrmann, R.2
Guillou, L.3
Honegger, H.P.4
Christinat, A.5
Fey, M.F.6
Sessa, C.7
Wernli, M.8
Cerny, T.9
Dietrich, D.10
Pestalozzi, B.11
-
51
-
-
0025120497
-
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma
-
DOI 10.1016/0277-5379(90)90075-5
-
J Schutte, et al. 1990 Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer. 26 5 558 561 2144740 1:STN:280: DyaK3czotVClsw%3D%3D (Pubitemid 20259327)
-
(1990)
European Journal of Cancer
, vol.26
, Issue.5
, pp. 558-561
-
-
Schutte, J.1
Mouridsen, H.T.2
Stewart, W.3
Santoro, A.4
Van Oosterom, A.T.5
Somers, R.6
Blackledge, G.7
Verweij, J.8
Dombernowsky, P.9
Thomas, D.10
Sylvester, R.11
-
52
-
-
22544453003
-
Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: Results of a phase II study
-
DOI 10.1002/cncr.21211
-
JM Siehl, et al. 2005 Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study Cancer. 104 3 611 617 15968689 1:CAS:528:DC%2BD2MXpt1els7o%3D (Pubitemid 41022820)
-
(2005)
Cancer
, vol.104
, Issue.3
, pp. 611-617
-
-
Siehl, J.M.1
Thiel, E.2
Schmittel, A.3
Hutter, G.4
Deckert, P.M.5
Szelenyi, H.6
Keilholz, U.7
-
53
-
-
16644397432
-
2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma
-
DOI 10.1200/JCO.2005.05.108
-
FP Worden, et al. 2005 Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma J Clin Oncol. 23 1 105 112 15625365 1:CAS:528:DC%2BD2MXpslaksQ%3D%3D (Pubitemid 41702628)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.1
, pp. 105-112
-
-
Worden, F.P.1
Taylor, J.M.G.2
Biermann, J.S.3
Sondak, V.K.4
Leu, K.M.5
Chugh, R.6
McGinn, C.J.7
Zalupski, M.M.8
Baker, L.H.9
-
54
-
-
0027280571
-
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas
-
K Antman, et al. 1993 An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas J Clin Oncol. 11 7 1276 1285 8315425 1:STN:280:DyaK3szgtFKlsw%3D%3D A randomized phase 3 study to determine the effects of adding ifosfamide to doxorubicin/dacarbazine. While addition of ifosfamide doubles ORR in a statistically significant manner, it increased toxicity and had no impact on overall survival (Pubitemid 23199130)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.7
, pp. 1276-1285
-
-
Antman, K.1
Crowley, J.2
Balcerzak, S.P.3
Rivkin, S.E.4
Weiss, G.R.5
Elias, A.6
Natale, R.B.7
Cooper, R.M.8
Barlogie, B.9
Trump, D.L.10
Doroshow, J.H.11
Aisner, J.12
Pugh, R.P.13
Weiss, R.B.14
Cooper, B.A.15
Clamond, G.H.16
Baker, L.H.17
-
55
-
-
0028335697
-
Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult
-
QG van Hoesel, et al. 1994 Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group Ann Oncol. 5 6 539 542 7918126 (Pubitemid 24223507)
-
(1994)
Annals of Oncology
, vol.5
, Issue.6
, pp. 539-542
-
-
Van Hoesel, Q.G.C.M.1
Verweij, J.2
Catimel, G.3
Clavel, M.4
Kerbrat, P.5
Van Oosterom, A.T.6
Kerger, J.7
Tursz, T.8
Van Glabbeke, M.9
Van Pottelsberghe, C.10
Le Bail, N.11
Mouridsen, H.12
-
56
-
-
0031709550
-
Phase II trial of paclitaxel in patients with soft-tissue sarcoma
-
ES Casper, et al. 1998 Phase II trial of paclitaxel in patients with soft-tissue sarcoma Cancer Investig. 16 7 442 446 1:CAS:528:DyaK1cXmvVOnu7c%3D (Pubitemid 28464852)
-
(1998)
Cancer Investigation
, vol.16
, Issue.7
, pp. 442-446
-
-
Casper, E.S.1
Waltzman, R.J.2
Schwartz, G.K.3
Sugarman, A.4
Pfister, D.5
Ilson, D.6
Woodruff, J.7
Leung, D.8
Bertino, J.R.9
-
57
-
-
55949086834
-
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: The ANGIOTAX Study
-
18809609 1:CAS:528:DC%2BD1cXhsVyqsrbJ
-
N Penel, et al. 2008 Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study J Clin Oncol. 26 32 5269 5274 18809609 1:CAS:528:DC%2BD1cXhsVyqsrbJ Although this is a small phase 2 study, it confirmed observations in other trials which suggested that paclitaxel single agent is active in angiosarcoma
-
(2008)
J Clin Oncol.
, vol.26
, Issue.32
, pp. 5269-5274
-
-
Penel, N.1
-
58
-
-
33745458519
-
Albumin-bound paclitaxel: A next-generation taxane
-
DOI 10.1517/14656566.7.8.1041
-
WJ Gradishar 2006 Albumin-bound paclitaxel: a next-generation taxane Expert Opin Pharmacother. 7 8 1041 1053 16722814 1:CAS:528:DC%2BD28XltVOgsrg%3D (Pubitemid 43949942)
-
(2006)
Expert Opinion on Pharmacotherapy
, vol.7
, Issue.8
, pp. 1041-1053
-
-
Gradishar, W.J.1
-
59
-
-
80051669940
-
A phase II study of nanoparticle albumin-bound (nab) paclitaxel in the treatment of patients with unresectable or metastatic sarcoma
-
• Butrynski JE, et al. A phase II study of nanoparticle albumin-bound (nab) paclitaxel in the treatment of patients with unresectable or metastatic sarcoma. CTOS Meeting Abstracts, 2010(Abstract #901186). Despite the negative data in this study for nab-paclitaxel as a single agent, this agent may hold potential if used as part of a combination regimen.
-
CTOS Meeting Abstracts, 2010(Abstract #901186)
-
-
Butrynski, J.E.1
-
60
-
-
0036900867
-
Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma
-
DOI 10.1097/00000421-200212000-00005
-
X Pivot, et al. 2002 Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma Am J Clin Oncol. 25 6 561 564 12477998 (Pubitemid 35453659)
-
(2002)
American Journal of Clinical Oncology: Cancer Clinical Trials
, vol.25
, Issue.6
, pp. 561-564
-
-
Pivot, X.1
Chevreau, C.2
Cupissol, D.3
Lortholary, A.4
Bui, N.-B.5
Eymard, J.-C.6
Bay, J.-O.7
Baranzelli, M.-C.8
Mita, M.9
Barnouin, L.10
Savary, J.11
Thyss, A.12
-
61
-
-
9144275042
-
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: A phase II study of the Hellenic Cooperative Oncology Group
-
DOI 10.1038/sj.bjc.6602148
-
D Bafaloukos, et al. 2004 Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group Br J Cancer. 91 9 1639 1644 15494721 1:CAS:528:DC%2BD2cXptVOhuro%3D (Pubitemid 39546134)
-
(2004)
British Journal of Cancer
, vol.91
, Issue.9
, pp. 1639-1644
-
-
Bafaloukos, D.1
Papadimitriou, C.2
Linardou, H.3
Aravantinos, G.4
Papakostas, P.5
Skarlos, D.6
Kosmidis, P.7
Fountzilas, G.8
Gogas, H.9
Kalofonos, C.10
Dimopoulos, A.M.11
-
62
-
-
53149109402
-
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: A mono-institutional phase II study
-
18351342 1:CAS:528:DC%2BD1cXhtF2kur%2FO
-
V Ferraresi, et al. 2008 Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study Cancer Chemother Pharmacol. 63 1 149 155 18351342 1:CAS:528:DC%2BD1cXhtF2kur%2FO
-
(2008)
Cancer Chemother Pharmacol.
, vol.63
, Issue.1
, pp. 149-155
-
-
Ferraresi, V.1
-
63
-
-
33646567780
-
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
-
DOI 10.1007/s10637-005-3537-1
-
JT Hartmann, et al. 2006 An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma Invest New Drugs. 24 3 249 253 16133789 1:CAS:528: DC%2BD28XktlWls7s%3D (Pubitemid 43723900)
-
(2006)
Investigational New Drugs
, vol.24
, Issue.3
, pp. 249-253
-
-
Hartmann, J.T.1
Oechsle, K.2
Huober, J.3
Jakob, A.4
Azemar, M.5
Horger, M.6
Kanz, L.7
Bokemeyer, C.8
-
64
-
-
0035424877
-
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation
-
SR Patel, et al. 2001 Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation J Clin Oncol. 19 15 3483 3489 11481354 1:CAS:528:DC%2BD3MXmtlGhurY%3D (Pubitemid 32730085)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.15
, pp. 3483-3489
-
-
Patel, S.R.1
Gandhi, V.2
Jenkins, J.3
Papadopolous, N.4
Burgess, M.A.5
Plager, C.6
Plunkett, W.7
Benjamin, R.S.8
-
65
-
-
0033911963
-
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas
-
DOI 10.1097/00001813-200006000-00002
-
E Spath-Schwalbe, et al. 2000 Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas Anticancer Drugs. 11 5 325 329 10912948 1:CAS:528:DC%2BD3cXltVegtLg%3D (Pubitemid 30459467)
-
(2000)
Anti-Cancer Drugs
, vol.11
, Issue.5
, pp. 325-329
-
-
Spath-Schwalbe, E.1
Genvresse, I.2
Koschuth, A.3
Dietzmann, A.4
Grunewald, R.5
Possinger, K.6
-
66
-
-
33644869706
-
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma
-
DOI 10.1097/01.coc.0000195088.28956.dd, PII 0000042120060200000012
-
G Von Burton, et al. 2006 Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma Am J Clin Oncol. 29 1 59 61 (Pubitemid 44356716)
-
(2006)
American Journal of Clinical Oncology: Cancer Clinical Trials
, vol.29
, Issue.1
, pp. 59-61
-
-
Von Burton, G.1
Rankin, C.2
Zalupski, M.M.3
Mills, G.M.4
Borden, E.C.5
Karen, A.6
-
67
-
-
34247586993
-
Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: Results of a phase II trial
-
DOI 10.1002/cncr.22609
-
P Dileo, et al. 2007 Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial Cancer. 109 9 1863 1869 17385194 1:CAS:528:DC%2BD2sXlsF2nu7o%3D (Pubitemid 46668552)
-
(2007)
Cancer
, vol.109
, Issue.9
, pp. 1863-1869
-
-
Dileo, P.1
Morgan, J.A.2
Zahrieh, D.3
Desai, J.4
Salesi, J.M.5
Harmon, D.C.6
Quigley, M.T.7
Polson, K.8
Demetri, G.D.9
George, S.10
-
68
-
-
33845366192
-
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas
-
DOI 10.1007/s00280-006-0263-0
-
R Losa, et al. 2007 Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas Cancer Chemother Pharmacol. 59 2 251 259 16736150 1:CAS:528:DC%2BD28Xht1GmsrfN (Pubitemid 44885154)
-
(2007)
Cancer Chemotherapy and Pharmacology
, vol.59
, Issue.2
, pp. 251-259
-
-
Losa, R.1
Fra, J.2
Lopez-Pousa, A.3
Sierra, M.4
Goitia, A.5
Una, E.6
Nadal, R.7
Del Muro, J.G.8
Gion, M.9
Maurel, J.10
Escudero, P.11
Esteban, E.12
Buesa, J.M.13
-
69
-
-
77955231655
-
Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study
-
• Garcia Del Muro X, et al. Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study. ASCO Meeting Abstracts. 2009;27(15S):10529. The combination of gemcitabine and dacarbazine appears very promising. It may have lower toxicity and similar efficacy to gemcitabine and docetaxel-based regimens. Awaiting publication of these results in formal manuscript.
-
(2009)
ASCO Meeting Abstracts
, vol.27
, Issue.15
, pp. 10529
-
-
Garcia Del Muro, X.1
-
70
-
-
2442635522
-
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma
-
DOI 10.1200/JCO.2004.08.043
-
KM Leu, et al. 2004 Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma J Clin Oncol. 22 9 1706 1712 15117993 1:CAS:528:DC%2BD2cXpsVWls78%3D Interesting in vitro data demonstrating that the sequential treatment of gemcitabine followed by docetaxel was synergistic, whereas simultaneous treatment led to antagonistic effects. Another component of this study is a retrospective analysis to identify the efficacy of gemcitabine/docetaxel by histologic subtype (Pubitemid 41079810)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.9
, pp. 1706-1712
-
-
Leu, K.M.1
Ostruszka, L.J.2
Shewach, D.3
Zalupski, M.4
Sondak, V.5
Sybil Biertnann, J.6
Lee, J.S.-J.7
Couwlier, C.8
Palazzolo, K.9
Baker, L.H.10
-
71
-
-
34548461654
-
Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and future
-
DOI 10.1634/theoncologist.12-8-999
-
RG Maki 2007 Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future Oncologist. 12 8 999 1006 17766660 1:CAS:528: DC%2BD2sXhtFWgsbnN (Pubitemid 47359143)
-
(2007)
Oncologist
, vol.12
, Issue.8
, pp. 999-1006
-
-
Maki, R.G.1
-
72
-
-
34447572873
-
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
-
DOI 10.1200/JCO.2006.10.4117
-
RG Maki, et al. 2007 Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected] J Clin Oncol. 25 19 2755 2763 17602081 1:CAS:528:DC%2BD2sXosValtLY%3D Randomized phase 2 trial of gemcitabine and docetaxel indicating significant activity over single-agent gemcitabine. Novel adaptive randomization strategy (Pubitemid 47123184)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.19
, pp. 2755-2763
-
-
Maki, R.G.1
Wathen, J.K.2
Patel, S.R.3
Priebat, D.A.4
Okuno, S.H.5
Samuels, B.6
Fanucchi, M.7
Harmon, D.C.8
Schuetze, S.M.9
Reinke, D.10
Thall, P.F.11
Benjamin, R.S.12
Baker, L.H.13
Hensley, M.L.14
-
73
-
-
80051664659
-
Phase II study of weekly docetaxel and fixed-dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma
-
Abstract #897230
-
Ahn J, et al. Phase II study of weekly docetaxel and fixed-dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. CTOS Meeting Abstracts, 2010(Abstract #897230).
-
(2010)
CTOS Meeting Abstracts
-
-
Ahn, J.1
-
74
-
-
80051665327
-
A phase II study of low dose TAG (taxotere, adriamycin, gemcitabine) as salvage therapy for soft tissue sarcoma
-
Abstract #896893
-
Ganjoo KN, et al. A phase II study of low dose TAG (taxotere, adriamycin, gemcitabine) as salvage therapy for soft tissue sarcoma. CTOS Meeting Abstracts, 2010(Abstract #896893).
-
(2010)
CTOS Meeting Abstracts
-
-
Ganjoo, K.N.1
-
75
-
-
79954902015
-
Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma
-
Seddon BM, et al. Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma. ASCO Meeting Abstracts. 2009;27(15S):10528.
-
(2009)
ASCO Meeting Abstracts
, vol.27
, Issue.15
, pp. 10528
-
-
Seddon, B.M.1
-
76
-
-
77955505177
-
A review of trabectedin (ET-743): A unique mechanism of action
-
20647340 Detailed description of the unique mechanisms of actions of this novel compound
-
M D'Incalci CM Galmarini 2010 A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther. 9 8 2157 2163 20647340 Detailed description of the unique mechanisms of actions of this novel compound
-
(2010)
Mol Cancer Ther.
, vol.9
, Issue.8
, pp. 2157-2163
-
-
D'Incalci, M.1
Galmarini, C.M.2
-
77
-
-
24944460785
-
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
-
16110008 1:CAS:528:DC%2BD2MXhtVersr%2FM
-
R Garcia-Carbonero, et al. 2005 Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol. 23 24 5484 5492 16110008 1:CAS:528:DC%2BD2MXhtVersr%2FM
-
(2005)
J Clin Oncol.
, vol.23
, Issue.24
, pp. 5484-5492
-
-
Garcia-Carbonero, R.1
-
78
-
-
77953888624
-
Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program
-
Blay J, et al. Trabectedin for advanced sarcomas failing doxorubicin: analysis of 189 unreported patients in a compassionate use program. ASCO Meeting Abstracts. 2009;27(15S):10574.
-
(2009)
ASCO Meeting Abstracts
, vol.27
, Issue.15
, pp. 10574
-
-
Blay, J.1
-
79
-
-
2342461682
-
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
-
DOI 10.1200/JCO.2004.02.098
-
R Garcia-Carbonero, et al. 2004 Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol. 22 8 1480 1490 15084621 1:CAS:528:DC%2BD2cXpt1yjurg%3D (Pubitemid 41103631)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.8
, pp. 1480-1490
-
-
Garcia-Carbonero, R.1
Supko, J.G.2
Manola, J.3
Seiden, M.V.4
Hannon, D.5
Ryan, D.P.6
Quigley, M.T.7
Merriam, P.8
Canniff, J.9
Goss, G.10
Matulonis, U.11
Maki, R.G.12
Lopez, T.13
Puchalski, T.A.14
Sancho, M.A.15
Gomez, J.16
Guzman, C.17
Jimeno, J.18
Demetri, G.D.19
-
80
-
-
20044372153
-
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
-
15659504
-
A Le Cesne, et al. 2005 Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol. 23 3 576 584 15659504
-
(2005)
J Clin Oncol.
, vol.23
, Issue.3
, pp. 576-584
-
-
Le Cesne, A.1
-
81
-
-
71649086663
-
Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute
-
Mohan V, et al. Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute. ASCO Meeting Abstracts. 2008;26(15 suppl):21506.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, Issue.15 SUPPL.
, pp. 21506
-
-
Mohan, V.1
-
82
-
-
80051666206
-
Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study
-
Samuels BL, et al. Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study. ASCO Meeting Abstracts. 2010;28(15 suppl):10027.
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 10027
-
-
Samuels, B.L.1
-
83
-
-
1542398698
-
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
-
DOI 10.1200/JCO.2004.05.210
-
A Yovine, et al. 2004 Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol. 22 5 890 899 14990645 1:CAS:528:DC%2BD2cXpsVKju7Y%3D (Pubitemid 41103601)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.5
, pp. 890-899
-
-
Yovine, A.1
Riofrio, M.2
Blay, J.Y.3
Brain, E.4
Alexandre, J.5
Kahatt, C.6
Taamma, A.7
Jimeno, J.8
Martin, C.9
Salhi, Y.10
Cvitkovic, E.11
Misset, J.L.12
-
84
-
-
70249101414
-
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules
-
19652065 1:CAS:528:DC%2BD1MXhtF2jtLrL
-
GD Demetri, et al. 2009 Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol. 27 25 4188 4196 19652065 1:CAS:528: DC%2BD1MXhtF2jtLrL
-
(2009)
J Clin Oncol.
, vol.27
, Issue.25
, pp. 4188-4196
-
-
Demetri, G.D.1
-
85
-
-
69249095786
-
Long-term benefit from trabectedin (T) in myxoid liposarcoma (MLS) patients
-
Grosso F, et al. Long-term benefit from trabectedin (T) in myxoid liposarcoma (MLS) patients. ASCO Meeting Abstracts. 2008;26(15 suppl):10582.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, Issue.15 SUPPL.
, pp. 10582
-
-
Grosso, F.1
-
86
-
-
76749100603
-
Advances in the treatment of gastrointestinal stromal tumor
-
19802531
-
D D'Adamo 2009 Advances in the treatment of gastrointestinal stromal tumor Adv Ther. 26 9 826 837 19802531
-
(2009)
Adv Ther.
, vol.26
, Issue.9
, pp. 826-837
-
-
D'Adamo, D.1
-
87
-
-
0037103424
-
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
-
DOI 10.1056/NEJMoa020461
-
GD Demetri, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med. 347 7 472 480 12181401 1:CAS:528:DC%2BD38XmtV2nt7s%3D (Pubitemid 34879334)
-
(2002)
New England Journal of Medicine
, vol.347
, Issue.7
, pp. 472-480
-
-
Demetri, G.D.1
Von Mehren, M.2
Blanke, C.D.3
Van Den Abbeele, A.D.4
Eisenberg, B.5
Roberts, P.J.6
Heinrich, M.C.7
Tuveson, D.A.8
Singer, S.9
Janicek, M.10
Fletcher, J.A.11
Silverman, S.G.12
Silberman, S.L.13
Capdeville, R.14
Kiese, B.15
Peng, B.16
Dimitrijevic, S.17
Druker, B.J.18
Corless, C.19
Fletcher, C.D.M.20
Joensuu, H.21
more..
-
88
-
-
0036305274
-
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
-
DOI 10.1053/hupa.2002.124122
-
RP Dematteo, et al. 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol. 33 5 466 477 12094371 1:CAS:528:DC%2BD38XlslCls7o%3D (Pubitemid 34747865)
-
(2002)
Human Pathology
, vol.33
, Issue.5
, pp. 466-477
-
-
Dematteo, R.P.1
Heinrich, M.C.2
El-Rifai, W.M.3
Demetri, G.4
-
89
-
-
15644363454
-
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
-
DOI 10.1126/science.279.5350.577
-
S Hirota, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science. 279 5350 577 580 9438854 1:CAS:528:DyaK1cXotVyhsw%3D%3D (Pubitemid 28067289)
-
(1998)
Science
, vol.279
, Issue.5350
, pp. 577-580
-
-
Hirota, S.1
Isozaki, K.2
Moriyama, Y.3
Hashimoto, K.4
Nishida, T.5
Ishiguro, S.6
Kawano, K.7
Hanada, M.8
Kurata, A.9
Takeda, M.10
Tunio, G.M.11
Matsuzawa, Y.12
Kanakura, Y.13
Shinomura, Y.14
Kitamura, Y.15
-
90
-
-
4644312266
-
Biology of gastrointestinal stromal tumors
-
DOI 10.1200/JCO.2004.05.140
-
CL Corless JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol. 22 18 3813 3825 15365079 1:CAS:528: DC%2BD2cXhtVCitb%2FL (Pubitemid 41095223)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.18
, pp. 3813-3825
-
-
Corless, C.L.1
Fletcher, J.A.2
Heinrich, M.C.3
-
91
-
-
80051666051
-
A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-{alpha} or -{beta} (PDGFR-{alpha}/PDGFR-{beta}): An Italian Sarcoma Group study
-
Grignani G, et al. A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-{alpha} or -{beta} (PDGFR-{alpha}/PDGFR-{beta}): An Italian Sarcoma Group study. ASCO Meeting Abstracts. 2010;28(15 suppl):10060.
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 10060
-
-
Grignani, G.1
-
92
-
-
78149452583
-
Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma
-
20953927 1:CAS:528:DC%2BC3cXht12qu7nJ
-
H Sugiura, et al. 2010 Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma J Orthop Sci. 15 5 654 660 20953927 1:CAS:528:DC%2BC3cXht12qu7nJ
-
(2010)
J Orthop Sci.
, vol.15
, Issue.5
, pp. 654-660
-
-
Sugiura, H.1
-
93
-
-
0142121411
-
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
-
DOI 10.1016/S0959-8049(02)00836-5
-
J Verweij, et al. 2003 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer. 39 14 2006 2011 12957454 1:CAS:528:DC%2BD3sXmvVKgtrc%3D (Pubitemid 37297756)
-
(2003)
European Journal of Cancer
, vol.39
, Issue.14
, pp. 2006-2011
-
-
Verweij, J.1
Van Oosterom, A.2
Blay, J.-Y.3
Judson, I.4
Rodenhuis, S.5
Van Der Graaf, W.6
Radford, J.7
Le Cesne, A.8
Hogendoorn, P.C.W.9
Di Paola, E.D.10
Brown, M.11
Nielsen, O.S.12
-
94
-
-
67650302850
-
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model
-
19451433 1:CAS:528:DC%2BD1MXhtFWitb3L
-
R Chugh, et al. 2009 Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model J Clin Oncol. 27 19 3148 3153 19451433 1:CAS:528:DC%2BD1MXhtFWitb3L
-
(2009)
J Clin Oncol.
, vol.27
, Issue.19
, pp. 3148-3153
-
-
Chugh, R.1
-
95
-
-
41549158178
-
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
-
18296418
-
JY Blay, et al. 2008 Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT) Ann Oncol. 19 4 821 822 18296418
-
(2008)
Ann Oncol.
, vol.19
, Issue.4
, pp. 821-822
-
-
Blay, J.Y.1
-
96
-
-
20844459809
-
Imatinib mesylate in chordoma
-
DOI 10.1002/cncr.20618
-
PG Casali, et al. 2004 Imatinib mesylate in chordoma Cancer. 101 9 2086 2097 15372471 1:CAS:528:DC%2BD2cXhtVShtb7J (Pubitemid 39425386)
-
(2004)
Cancer
, vol.101
, Issue.9
, pp. 2086-2097
-
-
Casali, P.G.1
Messina, A.2
Stacchiotti, S.3
Tamborini, E.4
Crippa, F.5
Gronchi, A.6
Orlandi, R.7
Ripamonti, C.8
Spreafico, C.9
Bertieri, R.10
Bertulli, R.11
Colecchia, M.12
Fumagalli, E.13
Greco, A.14
Grosso, F.15
Olmi, P.16
Pierotti, M.A.17
Pilotti, S.18
-
97
-
-
34247486113
-
A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis
-
Chugh R, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. ASCO Meeting Abstracts. 2006;24(18 suppl):9515.
-
(2006)
ASCO Meeting Abstracts
, vol.24
, Issue.18 SUPPL.
, pp. 9515
-
-
Chugh, R.1
-
98
-
-
77950469922
-
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials
-
20194851 1:CAS:528:DC%2BC3cXmtVyhu74%3D
-
P Rutkowski, et al. 2010 Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials J Clin Oncol. 28 10 1772 1779 20194851 1:CAS:528:DC%2BC3cXmtVyhu74%3D
-
(2010)
J Clin Oncol.
, vol.28
, Issue.10
, pp. 1772-1779
-
-
Rutkowski, P.1
-
99
-
-
67650312341
-
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
-
19451429 1:CAS:528:DC%2BD1MXhtFWitb3E
-
S George, et al. 2009 Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol. 27 19 3154 3160 19451429 1:CAS:528:DC%2BD1MXhtFWitb3E
-
(2009)
J Clin Oncol.
, vol.27
, Issue.19
, pp. 3154-3160
-
-
George, S.1
-
100
-
-
56149090573
-
Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas
-
Vigil CE, et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. ASCO Meeting Abstracts. 2008;26(15 suppl):10535.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, Issue.15 SUPPL.
, pp. 10535
-
-
Vigil, C.E.1
-
101
-
-
56749102511
-
Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505
-
Ryan CW, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. ASCO Meeting Abstracts. 2008;26(15 suppl):10532.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, Issue.15 SUPPL.
, pp. 10532
-
-
Ryan, C.W.1
-
102
-
-
67650293850
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
-
19451436 1:CAS:528:DC%2BD1MXhtFWitb3J
-
RG Maki, et al. 2009 Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol. 27 19 3133 3140 19451436 1:CAS:528:DC%2BD1MXhtFWitb3J
-
(2009)
J Clin Oncol.
, vol.27
, Issue.19
, pp. 3133-3140
-
-
Maki, R.G.1
-
103
-
-
67650337802
-
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)
-
19451427 1:CAS:528:DC%2BD1MXhtFWitb3P
-
S Sleijfer, et al. 2009 Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol. 27 19 3126 3132 19451427 1:CAS:528:DC%2BD1MXhtFWitb3P
-
(2009)
J Clin Oncol.
, vol.27
, Issue.19
, pp. 3126-3132
-
-
Sleijfer, S.1
-
104
-
-
84875158718
-
Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma
-
Schuetze S, et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. ASCO Meeting Abstracts. 2010;28(15 suppl):10009.
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 10009
-
-
Schuetze, S.1
-
105
-
-
56749170762
-
Angiogenesis inhibition in non-GIST soft tissue sarcomas
-
18987047 1:CAS:528:DC%2BD1MXmtVGjug%3D%3D
-
S Sleijfer WT van der Graaf JY Blay 2008 Angiogenesis inhibition in non-GIST soft tissue sarcomas Oncologist. 13 11 1193 1200 18987047 1:CAS:528:DC%2BD1MXmtVGjug%3D%3D
-
(2008)
Oncologist.
, vol.13
, Issue.11
, pp. 1193-1200
-
-
Sleijfer, S.1
Van Der Graaf, W.T.2
Blay, J.Y.3
-
106
-
-
76649116073
-
An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma
-
Agulnik M, et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. ASCO Meeting Abstracts. 2009;27(15S):10522.
-
(2009)
ASCO Meeting Abstracts
, vol.27
, Issue.15
, pp. 10522
-
-
Agulnik, M.1
-
107
-
-
77956395089
-
Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS)
-
• Verschraegen CF, et al. Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). ASCO Meeting Abstracts. 2008;26(15 suppl):10534. Although a small phase 2 trial, the combination of docetaxel, gemcitabine, and bevacizumab appears very promising.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, Issue.15 SUPPL.
, pp. 10534
-
-
Verschraegen, C.F.1
-
108
-
-
43549083034
-
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
-
DOI 10.1634/theoncologist.2008-0065
-
I Ray-Coquard, et al. 2008 A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens Oncologist. 13 4 467 473 18448563 1:CAS:528:DC%2BD1cXmslKksbY%3D A study where the targeted agent is not active despite the presence of molecular target in tumors. Underscores the significance of understanding the underlying biological mechanisms driving tumor progression. (Pubitemid 351679928)
-
(2008)
Oncologist
, vol.13
, Issue.4
, pp. 467-473
-
-
Ray-Coquard, I.1
Le Cesne, A.2
Whelan, J.S.3
Schoffski, P.4
Bui, B.N.5
Verweij, J.6
Marreaud, S.7
Van Glabbeke, M.8
Hogendoorn, P.9
Blay, J.-Y.10
-
109
-
-
80051668767
-
Phase II trial of cetuximab in patients (pts) with metastatic and/or locally advanced soft tissue and bone sarcomas
-
• Ha HT, et al. Phase II trial of cetuximab in patients (pts) with metastatic and/or locally advanced soft tissue and bone sarcomas. ASCO Meeting Abstracts. 2008;26(15 suppl):10537. A study where the targeted agent is not active despite the presence of molecular target in tumors. Underscores the significance of understanding the underlying biological mechanisms driving tumor progression.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, Issue.15 SUPPL.
, pp. 10537
-
-
Ha, H.T.1
-
110
-
-
62849105383
-
The insulin-like growth factor system and sarcomas
-
19148905 1:CAS:528:DC%2BD1MXjvFOmu7o%3D
-
B Rikhof, et al. 2009 The insulin-like growth factor system and sarcomas J Pathol. 217 4 469 482 19148905 1:CAS:528:DC%2BD1MXjvFOmu7o%3D
-
(2009)
J Pathol.
, vol.217
, Issue.4
, pp. 469-482
-
-
Rikhof, B.1
-
111
-
-
75449117196
-
A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas
-
Patel S, et al. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. ASCO Meeting Abstracts. 2009;27(15S):10503.
-
(2009)
ASCO Meeting Abstracts
, vol.27
, Issue.15
, pp. 10503
-
-
Patel, S.1
-
112
-
-
80051665996
-
A Phase II trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory bone and soft tissue sarcomas excluding ESFT
-
Abstract #900715
-
Pappo A, et al. A Phase II trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory bone and soft tissue sarcomas excluding ESFT. CTOS Meeting Abstracts, 2010(Abstract #900715).
-
(2010)
CTOS Meeting Abstracts
-
-
Pappo, A.1
-
113
-
-
77953641778
-
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: Twenty years from the bench to the bedside
-
20526094 1:CAS:528:DC%2BC3cXovV2rt74%3D
-
D Olmos, et al. 2010 Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside Cancer J. 16 3 183 194 20526094 1:CAS:528:DC%2BC3cXovV2rt74%3D
-
(2010)
Cancer J.
, vol.16
, Issue.3
, pp. 183-194
-
-
Olmos, D.1
-
114
-
-
79251591976
-
Updating progress in sarcoma therapy with mTOR inhibitors
-
20591820
-
JY Blay 2010 Updating progress in sarcoma therapy with mTOR inhibitors Ann Oncol. 22 2 280 287 20591820
-
(2010)
Ann Oncol.
, vol.22
, Issue.2
, pp. 280-287
-
-
Blay, J.Y.1
-
115
-
-
78751647387
-
Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST
-
Richter S, et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. ASCO Meeting Abstracts. 2010;28(15 suppl):10038.
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 10038
-
-
Richter, S.1
-
116
-
-
37149033966
-
Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial
-
• Chawla SP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial. ASCO Meeting Abstracts. 2007;25(18 suppl):10076. An example of a well-designed phase 2 trial that is based on promising evidence from phase 1 and 2 trials, Simon's two-stage design, sound statistical methods (enrolling an adequate number of patients), and segregated patients into cohorts based on their STS histological subtype.
-
(2007)
ASCO Meeting Abstracts
, vol.25
, Issue.18 SUPPL.
, pp. 10076
-
-
Chawla, S.P.1
-
117
-
-
34447535345
-
Engineering targeted viral vectors for gene therapy
-
DOI 10.1038/nrg2141, PII NRG2141
-
R Waehler SJ Russell DT Curiel 2007 Engineering targeted viral vectors for gene therapy Nat Rev Genet. 8 8 573 587 17607305 1:CAS:528: DC%2BD2sXnvVekt78%3D (Pubitemid 47077278)
-
(2007)
Nature Reviews Genetics
, vol.8
, Issue.8
, pp. 573-587
-
-
Waehler, R.1
Russell, S.J.2
Curiel, D.T.3
-
118
-
-
69949145988
-
Phase I/II and phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma
-
19532136 1:CAS:528:DC%2BD1MXntlGnsLw%3D
-
SP Chawla, et al. 2009 Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma Mol Ther. 17 9 1651 1657 19532136 1:CAS:528:DC%2BD1MXntlGnsLw%3D
-
(2009)
Mol Ther.
, vol.17
, Issue.9
, pp. 1651-1657
-
-
Chawla, S.P.1
-
119
-
-
80051663214
-
Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous Rexin-G as stand alone therapy for chemotherapy-resistant bone and soft tissue sarcoma
-
Abstract #896893
-
Ganjoo K, et al. Advanced phase I/II evaluation of tumor-targeted gene delivery: intravenous Rexin-G as stand alone therapy for chemotherapy-resistant bone and soft tissue sarcoma. CTOS Meeting Abstracts. 2010(Abstract #896893).
-
(2010)
CTOS Meeting Abstracts
-
-
Ganjoo, K.1
-
120
-
-
0030022252
-
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
-
DM Brizel, et al. 1996 Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res. 56 5 941 943 8640781 1:CAS:528:DyaK28XhtlKks7Y%3D (Pubitemid 26065381)
-
(1996)
Cancer Research
, vol.56
, Issue.5
, pp. 941-943
-
-
Brizel, D.M.1
Scully, S.P.2
Harrelson, J.M.3
Layfield, L.J.4
Bean, J.M.5
Prosnitz, L.R.6
Dewhirst, M.W.7
-
121
-
-
43049083694
-
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs
-
18257544 1:CAS:528:DC%2BD1cXhslWis7s%3D
-
JX Duan, et al. 2008 Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs J Med Chem. 51 8 2412 2420 18257544 1:CAS:528:DC%2BD1cXhslWis7s%3D
-
(2008)
J Med Chem.
, vol.51
, Issue.8
, pp. 2412-2420
-
-
Duan, J.X.1
-
122
-
-
79954499054
-
Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma
-
Cranmer LD, et al. Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma. ASCO Meeting Abstracts. 2010;28(15 suppl):10036.
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 10036
-
-
Cranmer, L.D.1
-
123
-
-
39149104690
-
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
-
DOI 10.1200/JCO.2007.12.7837
-
EL Korn, et al. 2008 Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials J Clin Oncol. 26 4 527 534 18235113 (Pubitemid 351264344)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.4
, pp. 527-534
-
-
Korn, E.L.1
Liu, P.-Y.2
Lee, S.J.3
Chapman, J.-A.W.4
Niedzwiecki, D.5
Suman, V.J.6
Moon, J.7
Sondak, V.K.8
Atkins, M.B.9
Eisenhauer, E.A.10
Parulekar, W.11
Markovic, S.N.12
Saxman, S.13
Kirkwood, J.M.14
-
124
-
-
27144523169
-
Gene expression profiling of human sarcomas: Insights into sarcoma biology
-
DOI 10.1158/0008-5472.CAN-05-1699
-
K Baird, et al. 2005 Gene expression profiling of human sarcomas: insights into sarcoma biology Cancer Res. 65 20 9226 9235 16230383 1:CAS:528:DC%2BD2MXhtFWmu7%2FO These references [124-126] highlight the potential of using high-throughput approaches to help understand the underlying biology of STS subtypes (Pubitemid 41507988)
-
(2005)
Cancer Research
, vol.65
, Issue.20
, pp. 9226-9235
-
-
Baird, K.1
Davis, S.2
Antonescu, C.R.3
Harper, U.L.4
Walker, R.L.5
Chen, Y.6
Glatfelter, A.A.7
Duray, P.H.8
Meltzer, P.S.9
-
125
-
-
5444251855
-
Role of gene expression arrays in sarcomas
-
KM Skubitz AP Skubitz 2004 Role of gene expression arrays in sarcomas Curr Oncol Rep. 6 4 309 314 15161587 These references [124-126] highlight the potential of using high-throughput approaches to help understand the underlying biology of STS subtypes (Pubitemid 39359501)
-
(2004)
Current Oncology Reports
, vol.6
, Issue.4
, pp. 309-314
-
-
Skubitz, K.M.1
Skubitz, A.P.N.2
-
126
-
-
33645054041
-
The role of microarray technologies in the study of soft tissue tumours
-
16359534 1:STN:280:DC%2BD2Mnnt1yrug%3D%3D
-
RB West M van de Rijn 2006 The role of microarray technologies in the study of soft tissue tumours Histopathology. 48 1 22 31 16359534 1:STN:280:DC%2BD2Mnnt1yrug%3D%3D These references [124-126] highlight the potential of using high-throughput approaches to help understand the underlying
-
(2006)
Histopathology.
, vol.48
, Issue.1
, pp. 22-31
-
-
West, R.B.1
Van De Rijn, M.2
-
127
-
-
23344454965
-
Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model
-
H Choi 2005 Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model Curr Oncol Rep. 7 4 307 311 15946591 This paper addresses lessons learned from GIST on how response to targeted agents is measured and evaluated (Pubitemid 41149677)
-
(2005)
Current Oncology Reports
, vol.7
, Issue.4
, pp. 307-311
-
-
Choi, H.1
-
128
-
-
0035154256
-
Clinical trial designs for cytostatic agents: Are new approaches needed?
-
EL Korn, et al. 2001 Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 19 1 265 272 11134222 1:CAS:528: DC%2BD3MXot1Wnsw%3D%3D A critical evaluation of appropriate end points, statistical considerations, and clinical trial designs for testing cytostatic agents (Pubitemid 32063505)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.1
, pp. 265-272
-
-
Korn, E.L.1
Arbuck, S.G.2
Pluda, J.M.3
Simon, R.4
Kaplan, R.S.5
Christian, M.C.6
-
129
-
-
0036189675
-
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
-
DOI 10.1016/S0959-8049(01)00398-7, PII S0959804901003987
-
M Van Glabbeke, et al. 2002 Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer. 38 4 543 549 11872347 An important paper characterizing the use of progression-free rate as a primary end point in STS trials (Pubitemid 34185394)
-
(2002)
European Journal of Cancer
, vol.38
, Issue.4
, pp. 543-549
-
-
Van Glabbeke, M.1
Verweij, J.2
Judson, I.3
Nielsen, O.S.4
|